Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s.
To ascertain whether CD4(+) lymphocyte increases induced by interleukin (IL)-2 enhanced in vivo immune responses, 38 human immunodeficiency virus (HIV)-infected patients who had received highly active antiretroviral therapy (HAART) or HAART and IL-2 for at least 60 weeks were immunized with tetanus toxoid, inactivated glycoprotein 120-depleted HIV-1, and hepatitis A and B vaccines. Despite dramatic increases in CD4(+) lymphocyte counts, IL-2 did not enhance immunization responses.
Valdez
Hernan
H
Case Western Reserve University and University Hospitals of Cleveland, Ohio 44106, USA. valdez.hernan@clevelandactu.org
Mitsuyasu
Ronald
R
Landay
Alan
A
Sevin
Anne D
AD
Chan
Ellen S
ES
Spritzler
John
J
Kalams
Spyros A
SA
Pollard
Richard B
RB
Fahey
John
J
Fox
Lawrence
L
Namkung
Ann
A
Estep
Scharla
S
Moss
Ronald
R
Sahner
David
D
Lederman
Michael M
MM
D016915:AIDS Vaccines / Q000276:immunology; D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology* / Q000187:drug effects* / Q000276:immunology; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology*; D022362:Hepatitis A Vaccines / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000276:immunology; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D008297:Male; D013745:Tetanus Toxoid / Q000276:immunology
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D019380:Anti-HIV Agents; D022362:Hepatitis A Vaccines; D017325:Hepatitis B Vaccines; D007376:Interleukin-2; D013745:Tetanus Toxoid